1-[2-(1H-Indol-3-yl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[2-(1H-Indol-3-yl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one
• 英文别名: 1-[2-(1H-indol-3-yl)ethyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5-one
• 化学式: C₂₁H₁₉N₅O
• 分子量: 357.415
• InChiKey: CSIYPJQZODIRND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• 1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1184385A1

  公开（公告）日：2002-03-06

  The invention relates to a dihydroimidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof: wherein : X represents hydrogen atoms, a sulphur atom or an oxygen atom; Y represents a bond, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridyl group optionally substituted; when Y represents a bond, a methylene group optionally substituted or a carbonyl group, then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a naphthyl group, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; the benzyl group, the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents; when Y represents an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted, then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a naphthyl group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; the benzyl group, the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents; and n represents 0 to 3. The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β.

  该发明涉及一种由化学式（I）表示的二氢咪唑并[1,2-a]嘧啶酮衍生物或其盐：其中：X代表氢原子、硫原子或氧原子；Y代表键、氧原子、硫原子、磺酰基、磺氧基、羰基、氮原子（可选择性取代）或取代的亚甲基基团；R1代表可选择性取代的2、3或4-吡啶基团；当Y代表键、可选择性取代的亚甲基基团或羰基时，R2代表C1-6烷基基团、C3-6环烷基基团、C1-2全氟烷基基团、C1-3卤代烷基基团、C1-4烷硫基团、C1-4烷氧基团、萘基团、苯硫基团、苄基团、苯环、吡啶环、吲哚环、吡咯环、噻吩环、呋喃环或咪唑环；苄基团、苯基、萘或环可选择性地被1至3个取代基取代；当Y代表氧原子、硫原子、磺酰基、磺氧基或氮原子（可选择性取代）时，R2代表C1-6烷基基团、C3-6环烷基基团、C1-2全氟烷基基团、C1-3卤代烷基基团、萘基团、苄基团、苯环、吡啶环、吲哚环、吡咯环、噻吩环、呋喃环或咪唑环；苄基团、苯基、萘或环可选择性地被1至3个取代基取代；n代表0至3。该发明还涉及一种药物，其包括所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病。
• Heteroaryl substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
  申请人：SANOFI-SYNTHELABO

  公开号：EP1340758A1

  公开（公告）日：2003-09-03

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X represents two hydrogen atoms, a sulphur atom, an oxygen atom or a C1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridine ring optionally substituted; R2 represents a heterocyclic bicyclic rings, having 1-4 heteroatoms selected from an oxygen atom, a sulfur atom and a nitrogen atom and having 5-9 carbon atoms, of formula R3 represents a hydrogen atom, a C1-6 alkyl group, a hydroxy group, a C1-4 alkoxy group or a halogen atom; R4 represents a hydrogen atom, a C1-6 alkyl group, a C1-4 alkoxy group or a halogen atom; The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  本发明涉及一种由公式（I）表示的嘧啶酮衍生物或其盐，其中：X代表两个氢原子，一个硫原子，一个氧原子或一个C1-2烷基基团和一个氢原子；Y代表键，乙烯基团，乙炔基团或者一个可选取代的亚甲基基团；R1代表一个可选取代的2,3或4-吡啶环；R2代表一个杂环双环环，具有1-4个从氧原子、硫原子和氮原子中选取的杂原子和5-9个碳原子，其化学式为；R3代表一个氢原子，一个C1-6烷基基团，一个羟基，一个C1-4烷氧基或者一个卤素原子；R4代表一个氢原子，一个C1-6烷基基团，一个C1-4烷氧基或者一个卤素原子。本发明还涉及一种药物，其中包括所述衍生物或其盐作为活性成分，可用于预防和/或治疗由GSK3β或GSK3β和cdk5/p25的异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-1,3-dihydoimidazo{1,2-a}pyrimidin-5(1h)one derivatives
  申请人：——

  公开号：US20040087598A1

  公开（公告）日：2004-05-06

  The invention relates to pyrimidone derivative represented by formula (I) or a salt thereof wherein X represents hydrogen atoms, a sulfur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, a 1,2-cyclopropylene, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represent a 2,3 or 4-pyridyl group optionally substituted by a C 3-6 cycloalkyl group a C 1-4 alkyl group, a C 1-4 alkoxy group, a benzyl group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represent a C 1-16 alkyl group, a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulfur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3&bgr; such as Alzheimer's disease.

  本发明涉及一种以式（I）表示的嘧啶酮衍生物或其盐，其中X代表氢原子、硫原子、氧原子或C1-2烷基和氢原子；Y代表键，乙烯基，乙炔基，1,2-环丙烷基，氧原子，硫原子，磺酰基，磺酸氧化物基，羰基，氮原子（可选择性取代）或取代的亚甲基基团；R1代表2,3或4-吡啶基团，可选择性取代为C3-6环烷基，C1-4烷基，C1-4烷氧基，苄基或卤原子；当Y代表键，可选择性取代的亚甲基基团或羰基时，则R2代表C1-16烷基，C3-6环烷基，C1-4烷硫基，C1-4烷氧基，C1-2全氟烷基，C1-3卤代烷基，5,6,7,8-四氢萘基环，萘基环，苯硫基，苄基，苯基环，吡啶基环，吲哚基环，吡咯基环，噻吩基环，呋喃基环或咪唑基环；当Y代表乙烯基，乙炔基，氧原子，硫原子，磺酰基，磺酸氧化物基或可选择性取代的氮原子时，则R2代表C1-6烷基，C3-6环烷基，C1-2全氟烷基，C1-3卤代烷基，萘基环，5,6,7,8-四氢萘基环，苄基，苯基环，吡啶基环，吲哚基环，吡咯基环，噻吩基环，呋喃基环或咪唑基环。本发明还涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，例如阿尔茨海默病。
• 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-one and 7-pyridinyl-2,3-dihydoimidazo[1,2-A]pyrimidin-5(1H)one derivatives
  申请人：Almario Garcia Antonio

  公开号：US20060014762A1

  公开（公告）日：2006-01-19

  The invention relates to a pyrimidone derivative represented by formula (I) or a salt thereof: wherein: X represents hydrogen atoms, a sulphur atom, an oxygen atom or a C 1-2 alkyl group and a hydrogen atom; Y represents a bond, an ethenylene group, an ethynylene group, a 1,2-cyclopropylene, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted; or a methylene group optionally substituted; R1 represents a 2, 3 or 4-pyridyl group optionally substituted by a C 3-6 cycloalkyl group a C 1-4 alkyl group, a C 1-4 alkoxy group, a benzyl group or a halogen atom; when Y represents a bond, a methylene group optionally substituted or a carbonyl group then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-4 alkylthio group, a C 1-4 alkoxy group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a 5,6,7,8-tetrahydronaphthyl ring, a naphthyl ring, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; when Y represents an ethenylene group, an ethynylene group, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted then R2 represents a C 1-6 alkyl group, a C 3-6 cycloalkyl group, a C 1-2 perhalogenated alkyl group, a C 1-3 halogenated alkyl group, a naphthyl ring, a 5,6,7,8-tetrahydronaphthyl ring, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring. And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative diseases caused by abnormal activity of GSK3β such as Alzheimer's disease.

  本发明涉及一种由式（I）或其盐所表示的嘧啶酮衍生物：其中：X代表氢原子，硫原子，氧原子或C1-2烷基和氢原子；Y代表键，乙烯基，乙炔基，1,2-环丙基，氧原子，硫原子，磺酰基，磺酸氧基，羰基，氮原子（可选地被取代）或取代的亚甲基基团；R1代表2、3或4-吡啶基团，可选地被C3-6环烷基，C1-4烷基，C1-4烷氧基，苄基或卤原子取代；当Y代表键，可选地被取代的亚甲基基团或羰基时，R2代表C1-6烷基，C3-6环烷基，C1-4烷硫基，C1-4烷氧基，C1-2全卤代烷基，C1-3卤代烷基，5,6,7,8-四氢萘基环，萘基环，苯基硫基，苄基，苯基环，吡啶基环，吲哚基环，吡咯基环，噻吩基环，呋喃基环或咪唑基环；当Y代表乙烯基，乙炔基，氧原子，硫原子，磺酰基，磺酸氧基或可选地被取代的氮原子时，R2代表C1-6烷基，C3-6环烷基，C1-2全卤代烷基，C1-3卤代烷基，萘基环，5,6,7,8-四氢萘基环，苄基，苯基环，吡啶基环，吲哚基环，吡咯基环，噻吩基环，呋喃基环或咪唑基环。本发明还涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病，如阿尔茨海默病。
• HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
  申请人：LOCHEAD Alistair

  公开号：US20070225300A1

  公开（公告）日：2007-09-27

  The invention relates to use of a pyrimidone derivative represented by formula (I) or a salt thereof wherein: X, Y, R1, R2, R3, R4, R5, m, n and p are as defined herein. In particular, the invention relates to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β or GSK3β and cdk5/p25, such as Alzheimer disease.

  本发明涉及使用由式（I）表示的嘧啶酮衍生物或其盐，其中：X，Y，R1，R2，R3，R4，R5，m，n和p如本文所定义。具体而言，本发明涉及一种药物，其包含所述衍生物或其盐作为活性成分，用于预防和/或治疗由GSK3β或GSK3β和cdk5/p25的异常活性引起的神经退行性疾病，如阿尔茨海默病。